*****GBA Buy->Enerpac Tool Group Corp. (EPAC)/ selling off after decent earn-- gobble gobble. NYSE - Nasdaq Real Time Price. Currency in USD $23.96-3.73(-13.47%)<----- GO TIME-!
I think our call on the rails is very timely- TRN Trinity Industries, Inc. 24.34 +0.51 +2.14% RAIL FreightCar America, Inc. 3.1900 +0.0300 +0.9494%
This gapped up and past me-- Travelzoo (TZOO) NasdaqGS - NasdaqGS Real Time Price. 5.57+0.99(+21.62%)<---------------------- As of 09:55AM EDT.
HEALTHCARE CDC Rings Alarm About Deadly Fungus. 6 Things to Know. Updated March 22, 2023 9:25 am ET / Original March 21, 2023 3:50 pm ET BARRON'S NEWSLETTERS The Barron's Daily The Candida auris fungus causes yeast infections. Here a scientist holds up a glass slide used for a run on a sequencing machine. The Centers for Disease Control and Prevention is sounding alarms this week about a dangerous fungus that has grown far more prevalent in the U.S. since the start of the Covid-19 pandemic, and poses a deadly threat, particularly in hospitals. It all sounds a bit like the setup for the HBO show The Last of Us, set after a fungal infection has effectively ended civilization. This fungus won’t lead to the next pandemic. But its resistance to antifungal medications, and its rapid spread across the U.S., is worrying, and new data from the CDC paints the fungus as an important threat for the healthcare system to confront. So what is the CDC so concerned about? Here is a brief primer. What Is Candida Auris? The fungus is known asCandida auris. First identified in 2009 in the ear of a patient at a Japanese hospital,C.auris is a yeast; one of hundreds of yeast species within the genus Candida.It is a cousin toC. albicans, a common yeast that causes infections like thrush. Other species of Candida can also cause infections, known generally as candidiasis. C. aurisfirst appeared in the U.S. in 2016, with a few cases popping up in New York City and Chicago. It’s now spread widely across the country, with infections seen in more than half of states across the U.S. The major worry for CDC officials is that most examples of the fungus seen in the U.S. are resistant to some of the medications used to control fungal infections, and a few are resistant to three major classes of antifungal medications used to fight candidiasis. How Much of a Health Threat DoesC. AurisPose? The fungus generally doesn’t pose a direct threat to healthy people, but it is often deadly in very ill people. The CDC says that people who are very sick, people who have invasive medical devices like breathing and feeding tubes, and people in healthcare facilities are at the highest risk. For these people, the fungus can be severe and often deadly. The CDC says that 30% to 60% of people with C. aurisinfections have died, though data is limited.!!!!!!!!!!! Why Are We Talking About This Now? CDC scientists on Monday evening published a paper in the scientific journal Annals of Internal Medicineon the spread ofC. aurisin the U.S. from 2019 to 2021. The scientists saw a 44% increase in clinical cases in 2019, and a 95% increase in 2021, as the fungus spread to 17 new states. Perhaps most worryingly, the number of cases ofC. auristhat were resistant to the most important therapy for candidiasis, known as echinocandins, tripled in 2021. The actual number ofC. auriscases remains relatively small, but is growing fast. The CDC experts counted 3,270 clinical infections since the fungus was first seen in the U.S. The number of cases has grown quickly, from 765 in 2020 to 1,471 in 2021. Antifungal resistance has been growing as well, the scientists found. Most samples ofC. auristested are resistant to a class of antifungals known as azoles, many are resistant to amphotericin B, and a small but growing number are resistant to echinocandins. The number of patients with infections that were resistant to echinocandins jumped to 15 in 2020, from 2 in 2018. While only four patients identified before 2020 had infections that were resistant to all three classes of antifungals, there were six such patients in 2020, and seven in 2021. “Although echinocandin resistance is still uncommon, the number of cases with echinocandin resistance is slowly increasing, with a substantial increase in 2021 and multiple outbreaks of these resistant strains raising concerns about transmission,” the scientist wrote. “Even this subtle increase is concerning because echinocandins are the first-line therapy for invasive Candida infections and mostC. aurisinfections.” Why Is This Happening? The CDC authors say that a number of factors likely contributed to the fungus’s spread, including a failure to identify cases ofC. aurisinfections early, and deficient infection control measures. They say that the explosion of cases during the heat of the Covid-19 pandemic may be due in part to strain that the pandemic placed on healthcare systems and the public health infrastructure. While the pandemic increased attention to some aspects of infection control, the paper suggests that other infection control measures not related to Covid-19 lagged behind during that period, allowing the fungus to spread in some healthcare settings. What Can Be Done to Stop the Fungus From Spreading? Most of the cases ofC. aurisin the U.S. occur in long-term acute care hospitals, where patients often have extended stays. The authors wrote that reducing the spread of the fungus will require “investment to improve case detection and infection control, particularly in long-term care facilities.” The paper’s lead author, a CDC epidemiologist named Dr. Meghan Lyman, said in a statement that the spread of the fungus “emphasizes the need for continued surveillance, expanded lab capacity, quicker diagnostic tests, and adherence to proven infection prevention and control.” Are Any Companies Working on Treatments for C. Auris? Yes, thanks in part to funding from the U.S. government’s Biomedical Advanced Research and Development Authority, which late last year announced fundingfor development of new antifungals. The biotech Scynexis(ticker: SCYX) is developing a novel antifungal called Ibrexafungerp that could treat C. auris, among other fungal infections. ScynexisSCYX+27.56% shares were up 31.2% on Tuesday.PfizerPFE–0.26%(PFE) is testing an antifungal called fosmanogepix, a drug it acquired in 2021 in its deal to buy the private biotech Amplyx Pharmaceuticals.
Warn me with what dude? The SPY is up 1.6% since March 10. It does that daily. My god Stoney, are you stupid? You need to get a trading account or something.
And for real Stoney... we are going lower. You confuse near term volatility with the bigger picture. Just watch. You'll see. When we hit 4200, I'll end this thread.